表觀遺傳診斷市場規模、佔有率和成長分析：按技術、應用、最終用戶和地區分類－2026-2033年產業預測

2024 年全球表觀遺傳診斷市場價值為 155 億美元，預計到 2033 年將從 2025 年的 180.6 億美元成長到 612.7 億美元，預測期（2026-2033 年）複合年成長率為 16.5%。

全球表觀遺傳診斷市場正經歷顯著成長，這主要得益於高通量定序和分析技術的進步。這些創新使得識別關鍵的表觀遺傳標記成為可能，例如DNA甲基化和組蛋白修飾，而這些標記對於疾病檢測至關重要。表觀遺傳學變化對於診斷和治療至關重要，因為它們是多種疾病的早期指標，標靶治療甚至可以逆轉這些變化。隨著定序和生物資訊學靈敏度的提高，預計表觀遺傳檢測的保險覆蓋範圍將擴大，從而加速其商業化進程。此外，對擴充性檢測平台的需求也將增加，尤其是在新型多癌种血液學檢測出現之後，這將促使診斷公司和定序技術提供者之間加強合作。這種協同效應將推動全球範圍內提供全面的癌症解決方案和孕前風險評估。

全球表觀遺傳診斷市場的成長要素

全球表觀遺傳診斷市場的主要促進因素之一是慢性病和癌症的日益普遍，這推動了對先進診斷工具的需求。隨著我們對疾病進展背後的表觀遺傳機制理解的不斷深入，對能夠提供個別患者特徵和個人化治療策略的創新診斷解決方案的需求也日益成長。此外，次世代定序和生物資訊學等技術的進步正在加速開發更精準、更經濟的表觀遺傳檢測方法，進一步促進市場成長，並拓展其在臨床和研究領域的應用範圍。

全球表觀遺傳診斷市場面臨的限制因素

全球表觀遺傳診斷市場的主要限制因素之一是先進診斷工具和技術的高成本。表觀遺傳分析需要複雜的技術，因此需要在研發和生產方面投入大量資金，導致醫療機構和病患都需承擔高昂的費用。此外，表觀遺傳資料的解讀複雜性也為臨床實務帶來挑戰，並可能限制醫療專業人員的採用。監管障礙和廣泛的檢驗研究需求也減緩了創新產品的上市速度，阻礙了市場准入，降低了患者和整個醫療保健系統的可及性。

全球表觀遺傳學診斷市場趨勢

全球表觀遺傳學診斷市場正經歷顯著成長，這主要得益於精準腫瘤學實踐的整合，這些實踐利用基於表觀遺傳學的診斷工具來增強患者分層。臨床醫生和研究人員日益認知到表觀遺傳標記在癌症診斷、預後和藥物反應預測方面的價值，這促進了診斷試劑製造商與腫瘤學領域之間的合作。這一趨勢為伴隨診斷的開發和臨床檢查室檢測方法的標準化鋪平了道路，最終支持個人化治療方法。隨著對實際應用和與臨床決策流程無縫整合的關注，腫瘤學表觀遺傳學診斷的未來正在形成。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球表觀遺傳診斷市場規模：依技術分類

• DNA甲基化
• 組蛋白修飾
• 非編碼RNA分析
• 其他

全球表觀遺傳診斷市場規模：按應用領域分類

• 腫瘤學
  • 利用液態生物檢體進行癌症篩檢
  • 固態腫瘤分析
• 心血管疾病
  • 中風風險評估
  • 心肌梗塞標記物
• 神經病學
• 其他

全球表觀遺傳診斷市場規模：依最終用戶分類

• 參考實驗室
• 醫院診斷檢查室
• 學術研究機構

全球表觀遺傳學診斷市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Thermo Fisher Scientific
• Illumina
• Merck KGaA
• Pacific Biosciences of California
• Bio-Rad Laboratories
• Qiagen
• Agilent Technologies
• Danaher Corporation
• Sysmex Corporation
• Revvity
• F. Hoffmann-La Roche
• Hologic
• Becton Dickinson
• Abbott Laboratories
• Siemens Healthineers
• Takara Bio
• Promega Corporation
• Eurofins Scientific
• Sonic Healthcare
• Quest Diagnostics

結論與建議

Global Epigenetics Diagnostics Market size was valued at USD 15.5 Billion in 2024 and is poised to grow from USD 18.06 Billion in 2025 to USD 61.27 Billion by 2033, growing at a CAGR of 16.5% during the forecast period (2026-2033).

The global epigenetics diagnostics market is experiencing significant growth, driven by advancements in high-throughput sequencing and analysis. These innovations enable the identification of critical epigenetic markers, including DNA methylation and histone modifications, which are vital for detecting disease. Epigenetic changes serve as early indicators of various conditions, making them crucial for diagnosis and treatment, as targeted therapies can potentially reverse these modifications. As sensitivity in sequencing and bioinformatics improves, reimbursement for epigenetic testing by payers is expected to increase, facilitating commercialization. Furthermore, the demand for scalable laboratory platforms will rise, particularly with emerging multi-cancer blood tests, prompting collaboration between diagnostic firms and sequencing technology providers. This synergy supports the delivery of comprehensive cancer solutions and preconception risk assessments worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Epigenetics Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Epigenetics Diagnostics Market Segments Analysis

Global epigenetics diagnostics market is segmented by technology, application, end-user and region. Based on technology, the market is segmented into DNA Methylation, Histone Modification, Non-Coding RNA Analysis and Others. Based on application, the market is segmented into Oncology, Cardiovascular Diseases, Neurology and Others. Based on end-user, the market is segmented into Reference Laboratories, Hospital Diagnostic Labs and Academic Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Epigenetics Diagnostics Market

One of the key market drivers for the global epigenetics diagnostics market is the increasing prevalence of chronic diseases and cancer, which have heightened the demand for advanced diagnostic tools. As the understanding of the epigenetic mechanisms underlying disease progression improves, there is a growing need for innovative diagnostic solutions that can provide insights into individual patient profiles and personalized treatment strategies. Additionally, advancements in technology, such as next-generation sequencing and bioinformatics, are facilitating the development of more accurate and cost-effective epigenetic tests, further propelling market growth and expanding applications in clinical and research settings.

Restraints in the Global Epigenetics Diagnostics Market

One of the key market restraints for the global epigenetics diagnostics market is the high cost associated with advanced diagnostic tools and technologies. The sophisticated nature of epigenetic analysis requires significant investment in research, development, and manufacturing, leading to elevated prices for both providers and patients. Additionally, the complexity of interpreting epigenetic data poses challenges in clinical settings, potentially limiting adoption among healthcare practitioners. Furthermore, regulatory hurdles and the need for extensive validation studies can slow down the introduction of innovative products, creating barriers for market entry and reducing overall accessibility for patients and healthcare systems.

Market Trends of the Global Epigenetics Diagnostics Market

The Global Epigenetics Diagnostics market is experiencing significant growth driven by the integration of precision oncology practices that leverage epigenetics-based diagnostic tools for enhanced patient stratification. Clinicians and researchers increasingly recognize the value of epigenetic markers in cancer diagnosis, prognosis, and drug response prediction, fostering collaboration between diagnostic manufacturers and the oncology sector. This trend is paving the way for the development of companion diagnostics and the standardization of assays in clinical laboratories, which, in turn, supports personalized therapy regimens. The emphasis on practical applications and seamless integration into clinical decision-making processes is shaping the future of epigenetic diagnostics in oncology.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Epigenetics Diagnostics Market Size by Technology & CAGR (2026-2033)

• Market Overview
• DNA Methylation
• Histone Modification
• Non-Coding RNA Analysis
• Others

Global Epigenetics Diagnostics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Oncology
  • Liquid Biopsy Cancer Screening
  • Solid Tumor Profiling
• Cardiovascular Diseases
  • Stroke Risk Assessment
  • Myocardial Infarction Markers
• Neurology
• Others

Global Epigenetics Diagnostics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Reference Laboratories
• Hospital Diagnostic Labs
• Academic Research Institutes

Global Epigenetics Diagnostics Market Size & CAGR (2026-2033)

• North America (Technology, Application, End-User)
  • US
  • Canada
• Europe (Technology, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Application, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific Biosciences of California
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Revvity
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton Dickinson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promega Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sonic Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations